References
- Swerdlow SH, Campo E, Harris NL, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
- Tefferi A. How I treat myelofibrosis. Blood 2011;117:3494–3504.
- Beer PA, Jones AV, Bench AJ, . Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 2009;144:904–908.
- Lambert JR, Everington T, Linch DC, . In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 2009;114:3018–3023.
- Polliack A, Prokocimer M, Matzner Y. Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol 1980;9:211–220.
- Camos M, Cervantes F, Montoto S, . Acute lymphoid leukemia following polycythemia vera. Leuk Lymphoma 1999;32:395–398.
- Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle 2007;6:550–566.
- Ma W, Zhang X, Wang X, . MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders. Diagn Mol Pathol 2011;20:34–39.
- Scott LM, Tong W, Levine RL, . JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459–468.
- Bercovich D, Ganmore I, Scott LM, . Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484–1492.
- Vainchenker W, Delhommeau F, Constantinescu SN, . New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118:1723–1735.
- Beer PA, Delhommeau F, LeCouedic JP, . Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010;115:2891–2900.
- Nakao M, Janssen JW, Seriu T, . Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using lightcycler technology. Leukemia 2000;14:312–315.
- Estrov Z. Stem cells and somatic cells: reprogramming and plasticity. Clin Lymphoma Myeloma Leuk 2009;9(Suppl. 3): S319–S328.